85 related articles for article (PubMed ID: 17257075)
41. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
42. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
43. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment.
Uchino J; Takayama K; Harada A; Kawakami Y; Inoue H; Curiel DT; Nakanishi Y
Cancer Gene Ther; 2005 Sep; 12(9):737-48. PubMed ID: 15861179
[TBL] [Abstract][Full Text] [Related]
44. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
[TBL] [Abstract][Full Text] [Related]
45. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K
J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153
[TBL] [Abstract][Full Text] [Related]
46. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
47. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis.
Kruyt FA; Curiel DT
Hum Gene Ther; 2002 Mar; 13(4):485-95. PubMed ID: 11874627
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
[TBL] [Abstract][Full Text] [Related]
49. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
Kanerva A; Zinn KR; Peng KW; Ranki T; Kangasniemi L; Chaudhuri TR; Desmond RA; Wang M; Takayama K; Hakkarainen T; Alfthan H; Stenman UH; Curiel DT; Hemminki A
Gene Ther; 2005 Jan; 12(1):87-94. PubMed ID: 15385953
[TBL] [Abstract][Full Text] [Related]
50. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
51. Characterization of Canine Adenovirus Type 2 Virus Infection Pattern in Canine and Human Cell Lines.
Hogans MD; Kretzschmar WP; Higgins TA; Chakrabortty A; Nance RL; Smith BF; Bedi D; Sandey M; Agarwal P
Adv Virol; 2022; 2022():3658970. PubMed ID: 36591003
[TBL] [Abstract][Full Text] [Related]
52. Pepsin digestion of virus particles in canine hepatitis using epon-embedded material.
Givan KF; Turnbull C; Jézéquel AM
J Histochem Cytochem; 1967 Aug; 15(11):688-94. PubMed ID: 4297607
[No Abstract] [Full Text] [Related]
53. Effect of canine adenovirus on JINET and Vero cells.
Murakami T; Kato H; Takada K
Nihon Juigaku Zasshi; 1977 Jun; 39(3):283-92. PubMed ID: 199776
[No Abstract] [Full Text] [Related]
54. An imbedded canine.
VENKATARAMANIYA H
J All India Dent Assoc; 1947; 19(4):126. PubMed ID: 18907820
[No Abstract] [Full Text] [Related]
55. Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients.
Agarwal P; Gammon EA; Sandey M; Lindley SS; Koehler JW; Matz BM; Smith AN; Kashentseva EA; Dmitriev IP; Curiel DT; Smith BF
Heliyon; 2021 Feb; 7(2):e06210. PubMed ID: 33615011
[TBL] [Abstract][Full Text] [Related]
56. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy.
Gómez A; Sardón D; Cejalvo T; Vázquez F; García-Castro J; Perisé-Barrios AJ
Mol Ther Oncolytics; 2020 Sep; 18():525-534. PubMed ID: 32995478
[TBL] [Abstract][Full Text] [Related]
57. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.
Béguin J; Nourtier V; Gantzer M; Cochin S; Foloppe J; Balloul JM; Laloy E; Tierny D; Klonjkowski B; Quemeneur E; Maurey C; Erbs P
BMC Vet Res; 2020 Aug; 16(1):307. PubMed ID: 32843040
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
59. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.
MacNeill AL; Weishaar KM; Séguin B; Powers BE
Viruses; 2018 Jul; 10(8):. PubMed ID: 30060548
[TBL] [Abstract][Full Text] [Related]
60. On the potential of oncolytic virotherapy for the treatment of canine cancers.
MacNeill AL
Oncolytic Virother; 2015; 4():95-107. PubMed ID: 27512674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
